AstraZeneca, mantle cell lymphoma

AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS
AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma
AstraZeneca’s (AZ) Calquence (acalabrutinib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for mantle cell lymphoma (MCL).
FDA Approves Two Breakthrough Cancer Treatments for AstraZeneca
New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for Patients
AstraZeneca’s Calquence combination approved in U.S.
Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the 15 products to be subject to IRA-prescripted price negotiations for Medicare this year.
FDA approves AstraZeneca's Calquence for untreated mantle cell lymphoma
Investing.com -- AstraZeneca (LON: AZN) in a stock exchange filing on Friday said that the FDA approved its drug Calquence (acalabrutinib) to treat previously untreated mantle cell lymphoma (MCL) in adults who cannot have a stem cell transplant.
AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.
AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. FDA approved its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) with chemoimmunotherapy as a first-line option for adults with mantle cell lymphoma,
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
FiercePharma3d
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
Hosted on MSN11h
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
pharmaphorum3d
AZ's Calquence gets first-line OK in mantle cell lymphoma
The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...
AstraZeneca's rare cancer drug Calquence gets US regulatory nod
AstraZeneca has announced that its Calquence drug has been approved in the US when used alongside chemoimmunotherapy for ...
Daily2d
USFDA approves AstraZeneca Calquence, bendamustine, rituximab combo for previously untreated mantle cell lymphoma
Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...